This clinical trial study aims to evaluate the effects of prolonged NaPB treatment in a
maximum of 20 patients with T2D. The primary objective is:
to investigate if prolonged boosting of ing BCAA oxidation will substantially lower plasma
glucose levels in patients with T2D.
Participants will undergo a Clinical randomized controlled trial (RCT) with a double-blinded,
placebo-controlled, cross-over design, including a wash-out period of 12 weeks. The trial
will contain 2 treatment arms, with each a duration of 12 weeks.
Participants will have a 12-week oral administration of 4.8 g/m2/day NaPB (in the form of
Pheburane) or placebo per day. Although depending on body surface area, ~21 g Pheburane needs
to be administered spread over the day 3 times taken with a meal.